BALTIMORE, Aug. 14, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that the new BD MAX™ MRSA molecular test has received a Moderate ...
BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: Genomic Vision (FR0011799907 – GV – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly ...
INDIANAPOLIS, Dec. 5, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated ...
Learn how a custom ADA assay was designed, incorporating acid dissociation with the ACE method to overcome drug interference using other standardized formats. Get the essential updates shaping the ...
CHICAGO — The use of a clinically validated flow cytometry test can assess type 1 and type 2 interferon activity in children with various pediatric inflammatory diseases to evaluate and monitor their ...
SAN DIEGO--(BUSINESS WIRE)--Assay Depot announced today that it raised $1.7 million from private investors. The funds will be used to expand the company's cloud-based pharmaceutical research platform.
ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance ...
IRVING, Texas, and OSAKA, Japan, Oct. 14, 2021 /PRNewswire/ -- Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and Ono ...
CALGARY, AB, July 9, 2025 /PRNewswire/ - Nanalysis Scientific Corp. (NSCI:CA) ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for ...
The "Global Oxidative Stress Assay Market for Pharmaceutical Industry 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global oxidative stress assay market for pharmaceutical ...
(RTTNews) - Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent ...